Work

A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer

Year: 2021

Type: article

Abstract: The majority (more than 90%) of male breast cancers (MaBCs) are estrogen receptor-positive, such that endocrine therapy is the mainstay of MaBC treatment. Endocrine therapy has been associated with improved overall survival in observational studies on MaBC, though large randomized clinical trials have never been completed to confirm this benefit in this population. Tamoxifen is currently the preferred drug for both metastatic and adjuvant treatment of MaBC. Known differences in treatment patterns and hormonal milieu between men and women may warrant a unique approach to the management of toxicities in men. This review provides a detailed discussion of endocrine therapy for MaBC.

Source: Breast Cancer Management

DOI: 10.2217/bmt-2021-0001

Authors: Siddhartha Yadav, Karthik V Giridhar, Jose Pablo Leone, Roberto A Leon-Ferre, Kathryn J Ruddy

Institutions: Mayo Clinic, Dana-Farber Cancer Institute

Language: English

Topic: Male Breast Health Studies

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,415